0001485003-21-000096.txt : 20210505 0001485003-21-000096.hdr.sgml : 20210505 20210505182234 ACCESSION NUMBER: 0001485003-21-000096 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210503 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Keyes Jason A CENTRAL INDEX KEY: 0001678152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36296 FILM NUMBER: 21895012 MAIL ADDRESS: STREET 1: 3344 NORTH TORREY PINES COURT STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sesen Bio, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Eleven Biotherapeutics, Inc. DATE OF NAME CHANGE: 20100223 4 1 wf-form4_162025333944120.xml FORM 4 X0306 4 2021-05-03 0 0001485003 Sesen Bio, Inc. SESN 0001678152 Keyes Jason A C/O SESEN BIO, INC. 245 FIRST STREET, SUITE 1800 CAMBRIDGE MA 02142 1 0 0 0 Stock Option 2.79 2021-05-03 4 A 0 92500 0 A 2031-05-03 Common Stock 92500.0 92500 D The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis. /s/ Monica Forbes, as attorney-in-fact 2021-05-05